The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! About 1.01 million shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 69.98% since March 8, 2016 and is uptrending. It has outperformed by 60.66% the S&P500.
The move comes after 5 months negative chart setup for the $222.74 million company. It was reported on Oct, 11 by Barchart.com. We have $7.15 PT which if reached, will make NASDAQ:CARA worth $26.73M less.
Analysts await Cara Therapeutics Inc (NASDAQ:CARA) to report earnings on November, 14. They expect $-0.47 earnings per share, down 147.37% or $0.28 from last year’s $-0.19 per share. After $-0.48 actual earnings per share reported by Cara Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.08% EPS growth.
Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage
Out of 3 analysts covering Cara Therapeutics (NASDAQ:CARA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 3 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, July 24 by Needham. The stock of Cara Therapeutics Inc (NASDAQ:CARA) has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald.
According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”
Insitutional Activity: The institutional sentiment decreased to 0.7 in 2016 Q2. Its down 0.32, from 1.02 in 2016Q1. The ratio dived, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Millennium Mgmt Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Tiaa Cref Inv Management Ltd Liability Com reported 134,155 shares or 0% of all its holdings. Janney Montgomery Scott Limited Company holds 0.02% or 94,117 shares in its portfolio. Magee Thomson Investment Prtn Limited Liability holds 0% or 89 shares in its portfolio. Bnp Paribas Arbitrage last reported 789 shares in the company. Morgan Stanley accumulated 0% or 42,717 shares. New York State Common Retirement Fund accumulated 19,600 shares or 0% of the stock. Tiverton Asset Ltd has 583,468 shares for 2.42% of their US portfolio. Legal General Group Public accumulated 0% or 3,710 shares. The Pennsylvania-based Susquehanna Gp Llp has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Geode Capital Mgmt Lc accumulated 0% or 119,201 shares. Wall Street Assocs, a California-based fund reported 192,300 shares. Northern Trust has 0% invested in the company for 216,644 shares. Cam Group Incorporated Holding A S has 0.02% invested in the company for 268,000 shares. Alliancebernstein L P, a New York-based fund reported 20,300 shares.
Insider Transactions: Since April 20, 2016, the stock had 0 insider buys, and 1 insider sale for $54,000 net activity. On Wednesday, April 20 the insider Menzaghi Frederique Ph.D. sold $54,000.
CARA Company Profile
Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.